Tripos and Chronogen Announce a Drug Discovery Partnership
Tripos to Provide Complete Drug Discovery Chemistry Services to Chronogen
Tripos, Inc. and Chronogen Inc. announced a three-year collaboration to discover and optimize small-molecule therapeutics for cardiovascular disorders.
Under the agreement, Tripos will employ its knowledge-driven chemistry process to provide complete drug discovery chemistry services for Chronogen. Drawing upon its proprietary chemical libraries, expertise in data analysis, design tools and rapid synthetic follow-up capabilities, Tripos will support Chronogen's biological expertise in metabolic pathways related to aging. Chronogen will apply its proprietary in vivo screening technologies to rapidly select effective molecules, and Tripos will collaborate with Chronogen to optimize them for specific cardiovascular indications.
Most read news
Other news from the department science
![Newsletter](https://img.chemie.de/assets/awportal/images/newsletter.png)
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.